Questions and Answers
What is the trade name of Calcitonin-Salmon?
Which classifications apply to Calcitonin-Salmon? (Select all that apply)
What routes are available for administering Calcitonin-Salmon?
What is the mechanism of action of Calcitonin-Salmon?
Signup and view all the answers
What are the indications for using Calcitonin-Salmon? (Select all that apply)
Signup and view all the answers
Which of the following are contraindications for Calcitonin-Salmon? (Select all that apply)
Signup and view all the answers
What are the pharmacokinetics of Calcitonin-Salmon?
Signup and view all the answers
What is the half-life (T1/2) of Calcitonin-Salmon?
Signup and view all the answers
What are common adverse effects of Calcitonin-Salmon? (Select all that apply)
Signup and view all the answers
What patient teaching should be provided for those using Calcitonin-Salmon? (Select all that apply)
Signup and view all the answers
Study Notes
Calcitonin-Salmon Overview
- Trade name: Miacalcin, used for various medical conditions.
Classification
- Belongs to hypocalcemics and hormones which regulate calcium levels in the body.
Routes of Administration
- Administered intranasally, intramuscularly (IM), or subcutaneously (SQ) based on patient needs.
Mechanism of Action
- Inhibits osteoclast activity, reducing bone resorption.
- Decreases tubular resorption of calcium, leading to increased calcium excretion.
Indications
- Effective in treating postmenopausal osteoporosis.
- Used in Paget's disease of bone and in cases of hypercalcemia.
Contraindications
- Not suitable for individuals with hypersensitivity to calcitonin, salmon, or gelatin.
- Use during pregnancy or lactation is not recommended.
Pharmacokinetics
- Absorption: Complete with IM/SQ administration; rapid absorption with intranasal route.
- Distribution: Not well understood.
- Metabolism: Rapidly metabolized in kidneys, blood, and tissues.
Half-Life
- T1/2 ranges from 40 to 90 minutes, impacting dosing frequency.
Adverse Effects
- Risk of allergic reactions, including anaphylaxis.
- Intranasal use may lead to nasal dryness or irritation; potential association with nasal malignancy.
- 10% incidence of nausea with IM/SQ use; possible inflammatory reactions at the injection site.
- Therapeutic effects may diminish after one year of use.
Patient Teaching
- Monitor for signs of fever, hives, and anaphylaxis post-administration.
- Check nasal passages for ulcerations during intranasal use and discontinue if necessary.
- Educate patients on the risk of nasal malignancy associated with prolonged use.
- Nausea may decrease with continued therapy; ensure patients are aware.
- Advise regular monitoring of serum calcium levels, aiming for normalization within months.
Studying That Suits You
Use AI to generate personalized quizzes and flashcards to suit your learning preferences.
Description
Test your knowledge on Calcitonin-Salmon with these flashcards. The quiz covers important details such as trade names, classification, routes of administration, mechanism of action, and indications. Perfect for students in pharmacology or medicine.
